课题基金 / 基金详情

TRANSFORMATION OF HUMAN BREAST EPITHELIAL CELLS IN VITRO

TRANSFORMATION OF HUMAN BREAST EPITHELIAL CELLS IN VITRO
人乳腺上皮细胞的体外转化
批准号:
3193405
负责人:
Satyabrata Nandi
金额:
$20.05万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-07-01 至 1994-05-31

项目摘要

项目成果

Satyabrata Nandi的其他基金

相似基金

相关文献

中文摘要
翻译
我们的长期目标是诱发癌前病变和肿瘤 人乳腺上皮细胞的转化,定义如下 体外条件,含有直接和间接作用的化学物质 致癌物质。始终如一地改变人类乳房的能力 在确定的体外条件下的细胞对于设计是必不可少的 理解潜在细胞-分子事件的实验 人乳腺癌的转化和组织发生(S)。我们的 策略是将在血清中生长的人上皮细胞- 在胶原凝胶培养系统中的游离条件,以及在 使用各种基质的单层培养系统。具体来说, 我们将:a)分析正常、良性的生长规律 (纤维囊性)和癌性人乳腺细胞中的胶原 在激素存在的无血清条件下进行培养 (雌激素、黄体酮、催乳素等)、生长因子(EGF、 成纤维细胞生长因子、转化生长因子α、转化生长因子β等)和非激素性药物(脂类、 TPA,Li+);b)使用这些端点来设计文化条件 促进人乳腺上皮细胞转化的基因 高产,其方式类似于为 转化小鼠上皮细胞;c)使用cDNA探针 确定是否扩增、重排或表达 纤溶酶原激活物(tPA、尿激活酶)、转化生长因子α、转化生长因子β、表皮生长因子 谷胱甘肽-S-转移酶-P,γ-谷氨酰受体 转肽酶和0-6烷基-DNA-烷基转移酶是可靠的, 转化与肿瘤的定量分子标记物 组织发生;d)确定是否在分子水平上发生变化 与表型变化相关(核型、免疫细胞化学、 超微结构);e)建立适合体外和体内的检测方法 系统来识别那些分子细胞的变化, 代表癌前病变和肿瘤(恶性)转化子。 我们的经验和方法建议开发一个系统(S) 对人乳腺上皮细胞的体外转化是一种 可实现的目标。
英文摘要
Our long term objective is to induce preneoplastic and neoplastic transformation of human mammary epithelial cells, under defined in vitro conditions, with direct- and indirect-acting chemical carcinogens. An ability to consistently transform human mammary cells under defined in vitro conditions is essential to designing experiments to understand the cellular-molecular events underlying transformation and histogenesis of human breast cancer(s). Our strategy is to transform human epithelial cells grown under serum- free conditions in a collagen gel culture system, as well as in monolayer culture systems using various matrices. Specifically, we will: a) analyze the growth regulation of normal, benign (fibrocystic) and carcinomatous human mammary cells in collagen culture, under serum-free conditions in the presence of hormones (estrogen, progesterone, prolactin, etc.), growth factors (EGF, FGF, TGF alpha, TGF beta, etc.) and nonhormonal agents (lipids, TPA, Li+); b) use these endpoints to design culture conditions which facilitate human mammary epithelial cell transformation at high yield, in a manner similar to those developed for transformation of murine epithelial cells; c) use cDNA probes to determine whether amplification, rearrangement or expression of plasminogen activators (tPA, urokinase), TGF alpha, TGF beta, EGF receptor, glutathione-s-transferase-P, gamma-glutamyl transpeptidase and 0-6 alkyl-DNA-alkyltransferase are reliable, quantitative molecular markers for transformation and tumor histogenesis; d) determine whether changes at the molecular level correlate with phenotype changes (karyotypic, immunocytochemical, ultramicroscopic); e) develop suitable in vitro and in vivo assay systems to identify those molecular-cellular changes which represent preneoplastic and neoplastic (malignant) transformants. Our experience and approach suggest that development of a system(s) for transformation of human mammary epithelial cell in vitro is an achievable goal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PARITY RESISTANCE TO MAMMARY CANCER--MOLECULAR ANALYSES
  • 批准号:
    6173700
  • 项目类别:
  • 资助金额:
    $21.83万
  • 财政年份:
    1999
  • 负责人:
    Satyabrata Nandi
  • 依托单位:
PARITY RESISTANCE TO MAMMARY CANCER--MOLECULAR ANALYSES
PARITY RESISTANCE TO MAMMARY CANCER--MOLECULAR ANALYSES
  • 批准号:
    6513247
  • 项目类别:
  • 资助金额:
    $23.16万
  • 财政年份:
    1999
  • 负责人:
    Satyabrata Nandi
  • 依托单位:
PARITY RESISTANCE TO MAMMARY CANCER--MOLECULAR ANALYSES
  • 批准号:
    6376792
  • 项目类别:
  • 资助金额:
    $22.49万
  • 财政年份:
    1999
  • 负责人:
    Satyabrata Nandi
  • 依托单位:
国内基金
海外基金
ITS-HPLC-HRMS-Bioassay多级筛选策略指导下海洋真菌中新型抗菌活性产物的发现